Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Development of Therapeutic Vaccination Technology (TherVacB vaccine)
4.1.1.2. Signing Memoranda of Understanding (MoUs) with leading generic manufacturers to secure historic ceiling prices for life-saving hepatitis B and C treatments
4.1.2. Restraints
4.1.2.1. High Doses of Medications Lead to the Complication of Reactivation of the Hepatitis B Virus
4.1.3. Opportunity
4.1.3.1. Advancements in Hepatitis B Treatment
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Acute*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chronic
9. By Treatment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment
9.2. Immune modulator Drugs*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Interferon Alpha (Intron A)
9.2.4. Pegylated Interferon (Pegasys)
9.3. Antiviral Drugs
9.3.1. Tenofovir disoproxil (Viread)
9.3.2. Tenofovir alafenamide (Vemlidy)
9.3.3. Entecavir (Baraclude)
9.3.4. Telbivudine (Tyzeka or Sebivo)
9.3.5. Adefovir Dipivoxil (Hepsera)
9.3.6. Lamivudine (Epivir-HBV, Zeffix, or Heptodin)
9.3.7. Others
9.4. Vaccines
9.4.1. Combination Vaccine
9.4.2. Single Antigen Vaccine
9.5. Surgery
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. U.K.
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Spain
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies
13. Company Profiles
13.1. Bristol-Myers Squibb*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Gilead Sciences, Inc.
13.3. GlaxoSmithKline
13.4. Accord Healthcare Inc.
13.5. Apotex Corp.
13.6. Arbutus Biopharma
13.7. Arrowhead Pharma
13.8. Aurobindo Pharma Limited
13.9. Lupin Pharmaceuticals Inc.
13.10. Merck & Co. Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us